Bristol Myers Squibb Company has been preparing for a long time to launch its most recently approved product, the TYK2 inhibitor Sotyktu (deucravacitinib). And with its first dermatology drug, the company has set a big goal – to become the new standard of care for treating psoriasis with an oral therapy, unseating Amgen, Inc.’s established PDE4 inhibitor Otezla (apremilast).
The US Food and Drug Administration approved Sotyktu for the treatment of moderate-to-severe plaque psoriasis on 9 September with a...
